#1 Clinical Trials Search in Europe

Allogenic Bone Marrow-Derived Mesenchymal Stem Cells Transduced With Icovir-5, Ex Vivo Expanded

AloCelyvir, a novel cell therapy using allogenic bone marrow-derived mesenchymal stem cells transduced with Icovir-5, is being investigated in clinical trials for various challenging cancers. This article explores the potential of AloCelyvir in treating conditions such as diffuse intrinsic pontine glioma (DIPG), medulloblastoma, metastatic uveal melanoma, and relapsed or refractory extracranial solid tumors in children and adolescents. We’ll delve into the ongoing clinical trials, their objectives, and the potential impact of this innovative treatment approach.

Table of Contents

What is AloCelyvir?

AloCelyvir is an innovative cell therapy medication being studied for the treatment of various types of cancer[1]. It is classified as a somatic cell therapy medicinal product, which means it uses cells from the human body as a treatment[2]. The full name of the active substance in AloCelyvir is “allogenic bone marrow-derived mesenchymal stem cells transduced with ICOVIR-5, ex vivo expanded”[1].

To break this down into simpler terms:

  • Allogenic means the cells come from a donor, not the patient themselves.
  • Bone marrow-derived mesenchymal stem cells are a type of adult stem cell found in bone marrow that can develop into various cell types.
  • Transduced with ICOVIR-5 means these cells have been modified with a special virus called ICOVIR-5.
  • Ex vivo expanded means the cells are grown and multiplied in a laboratory before being given to patients.

How Does AloCelyvir Work?

AloCelyvir works by combining two approaches to fight cancer[1]:

  1. Stem Cell Therapy: The mesenchymal stem cells in AloCelyvir can potentially help repair damaged tissues and modulate the immune system.
  2. Viral Therapy: The ICOVIR-5 virus that’s introduced into the stem cells is designed to target and kill cancer cells specifically.

This combination is intended to create a powerful anti-cancer effect, potentially helping the body fight cancer more effectively than traditional treatments alone[2].

Conditions Treated with AloCelyvir

AloCelyvir is being studied for several types of cancer, particularly in children, adolescents, and young adults. These include[1][2][3]:

  • Diffuse Intrinsic Pontine Glioma (DIPG): A rare and aggressive brain tumor that occurs in children.
  • Medulloblastoma: Another type of brain tumor that primarily affects children.
  • Metastatic Uveal Melanoma: A type of eye cancer that has spread to other parts of the body.
  • Relapsed or Refractory Extracranial Solid Tumors: Various types of solid tumors outside the brain that have come back after treatment or didn’t respond to initial treatments.

Current Clinical Trials

AloCelyvir is currently being studied in several clinical trials[1][2][3]:

  1. DIPG and Medulloblastoma Trial: This study is testing AloCelyvir in children, adolescents, and young adults with newly diagnosed DIPG or relapsed/progressing medulloblastoma.
  2. Metastatic Uveal Melanoma Trial: This trial is studying AloCelyvir in adult patients with metastatic uveal melanoma.
  3. Extracranial Solid Tumors Trial: This study is looking at combining AloCelyvir with chemotherapy and radiotherapy in children and adolescents with relapsed or refractory extracranial solid tumors.

How is AloCelyvir Administered?

AloCelyvir is given as an intravenous infusion, which means it’s delivered directly into the bloodstream through a vein[1]. The exact dosing schedule and frequency may vary depending on the specific clinical trial and the patient’s condition.

Potential Side Effects

As AloCelyvir is still in clinical trials, all potential side effects may not be known yet. The trials are designed to carefully monitor for any adverse reactions[1][2][3]. Patients in the trials are closely watched for:

  • Dose-limiting toxicities
  • Immune reactions
  • Any unexpected side effects

It’s important to note that potential risks and side effects are always carefully weighed against the potential benefits in cancer treatment, especially for aggressive or hard-to-treat cancers.

Future Prospects

AloCelyvir represents an exciting new approach in cancer treatment, combining cell therapy with targeted viral therapy. If the current clinical trials show positive results, it could potentially offer new hope for patients with difficult-to-treat cancers, particularly in pediatric populations[1][2][3].

However, it’s important to remember that AloCelyvir is still in the experimental stage. More research is needed to fully understand its effectiveness and safety profile. Patients and families interested in this treatment should discuss it with their healthcare providers and consider participation in clinical trials if appropriate.

Trial Name Cancer Type Age Group Primary Objective
2022-502516-37-00 DIPG and Medulloblastoma 1-21 years Evaluate safety of AloCelyvir with radiotherapy (DIPG) or as monotherapy (Medulloblastoma)
2024-515032-76-00 Metastatic Uveal Melanoma ≥18 years Evaluate efficacy of AloCelyvir in terms of response rate
2024-518417-25-00 Relapsed/Refractory Extracranial Solid Tumors 1-21 years Evaluate safety of AloCelyvir combined with chemotherapy and radiotherapy

FAQ

  • What is AloCelyvir? AloCelyvir is a cell therapy made from allogenic bone marrow-derived mesenchymal stem cells that have been modified with a virus called Icovir-5. It's being studied as a potential treatment for various challenging cancers, especially in children and young adults.
  • What types of cancers is AloCelyvir being tested for? AloCelyvir is currently being tested in clinical trials for diffuse intrinsic pontine glioma (DIPG), medulloblastoma, metastatic uveal melanoma, and relapsed or refractory extracranial solid tumors in children and adolescents.
  • How is AloCelyvir administered? AloCelyvir is administered through intravenous infusion, which means it's given directly into the bloodstream through a vein.
  • What are the main objectives of the AloCelyvir clinical trials? The main objectives of the clinical trials include evaluating the safety and efficacy of AloCelyvir, assessing its combination with other treatments like chemotherapy and radiotherapy, and measuring outcomes such as tumor response, progression-free survival, and overall survival.
  • Who can participate in AloCelyvir clinical trials? Eligibility varies by trial, but generally includes patients aged 1 to 21 years with specific cancer types who meet certain health criteria. Some trials also include adult patients. Detailed eligibility criteria are provided for each specific trial.

Ongoing Clinical Trials on Allogenic Bone Marrow-Derived Mesenchymal Stem Cells Transduced With Icovir-5, Ex Vivo Expanded

  • Study on the Safety of Repeated Intra-Arterial Infusion of Mesenchymal Stem Cells for Children and Adolescents with Refractory Epilepsy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on AloCelyvir with Chemotherapy and Radiotherapy for Children and Adolescents with Relapsed or Refractory Extracranial Solid Tumors

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of AloCelyvir for Patients with Metastatic Uveal Melanoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Safety and Efficacy of AloCelyvir for Children, Adolescents, and Young Adults with Diffuse Intrinsic Pontine Glioma or Medulloblastoma.

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Allogenic: Refers to cells or tissues that are taken from a different individual of the same species, rather than from the patient themselves.
  • Mesenchymal Stem Cells: A type of adult stem cell that can develop into various cell types, including bone, cartilage, muscle, and fat cells.
  • Icovir-5: A modified virus used to alter the mesenchymal stem cells in AloCelyvir therapy.
  • Diffuse Intrinsic Pontine Glioma (DIPG): A rare and aggressive type of brain tumor that occurs in children, located in the brainstem.
  • Medulloblastoma: A cancerous brain tumor that starts in the lower back part of the brain, called the cerebellum.
  • Uveal Melanoma: A type of eye cancer that develops in the uvea, the pigmented layer of the eye.
  • Extracranial Solid Tumors: Cancerous tumors that occur outside the brain and spinal cord.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease but it does not get worse.
  • Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • RECIST Criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Dose-Limiting Toxicity: Side effects of a treatment that are severe enough to prevent an increase in dose or require a dose reduction.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-efficacy-of-alocelyvir-for-children-adolescents-and-young-adults-with-diffuse-intrinsic-pontine-glioma-or-medulloblastoma/
  2. http://clinicaltrials.eu/trial/study-of-alocelyvir-for-patients-with-metastatic-uveal-melanoma/
  3. http://clinicaltrials.eu/trial/study-on-alocelyvir-with-chemotherapy-and-radiotherapy-for-children-and-adolescents-with-relapsed-or-refractory-extracranial-solid-tumors/